Raymond James analyst Reni Benjamin maintained a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) today. The company’s shares opened today at $11.10.
Benjamin noted:
“We are maintaining our Outperform rating for ADAP. Today, Adaptimmune announced preliminary safety data from an ongoing Phase I/II study evaluating the MAGE-A10 SPEAR T-cells in non-small cell lung cancer (NSCLC). With no off-target toxicity or alloreactivity seen in the 3 patients in cohort 2 treated with 1 billion MAGE-A10 cells, the study has received the greenlight from an independent safety review committee (SRC) to proceed to continue to dose up to 6 billion cells in conjunction with a higher intensity preconditioning regiment.”
According to TipRanks.com, Benjamin is a 4-star analyst with an average return of 7.1% and a 44.7% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Spark Therapeutics, and TG Therapeutics.
Currently, the analyst consensus on Adaptimmune Therapeutics is a Strong Buy with an average price target of $19.
See today’s analyst top recommended stocks >>
The company has a one-year high of $14.63 and a one-year low of $4.82. Currently, Adaptimmune Therapeutics has an average volume of 393.1K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors.
